STRATA Skin Sciences Board Changes

TL;DR

STRATA Skin Sciences swapped a director and added a new one, plus some executive pay details.

AI Summary

STRATA Skin Sciences, Inc. announced on November 13, 2024, a change in its Board of Directors. Specifically, the company reported the departure of Director Michael L. Culhane and the election of Dr. Robert E. Grant as a new director. The filing also includes information regarding compensatory arrangements for certain officers.

Why It Matters

Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Board changes can introduce uncertainty regarding strategic direction and management stability.

Key Players & Entities

• STRATA Skin Sciences, Inc. (company) — Registrant
• Michael L. Culhane (person) — Departing Director
• Dr. Robert E. Grant (person) — Newly Elected Director
• November 13, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share SSKN The NASDAQ

Filing Documents

• ef20038566_8k.htm (8-K) — 32KB
• ef20038566_ex99-1.htm (EX-99.1) — 117KB
• image0.jpg (GRAPHIC) — 194KB
• 0001140361-24-046508.txt ( ) — 782KB
• sskn-20241113.xsd (EX-101.SCH) — 4KB
• sskn-20241113_lab.xml (EX-101.LAB) — 21KB
• sskn-20241113_pre.xml (EX-101.PRE) — 16KB
• ef20038566_8k_htm.xml (XML) — 4KB

02

Item 2.02. Results of Operations and Financial Condition. On November 13, 2024, STRATA Skin Sciences, Inc. (the "Company") issued a press release announcing its results of operations for the first fiscal quarter ended June 30, 2024 . The full text of such press release is furnished as Exhibit 99.1 to this report. The information set forth under this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 13, 2024, Strata Skin Sciences, Inc. (the "Company") designated its Vice President Finance, John Gillings, as its principal financial officer and principal accounting officer. Mr. Gillings, age 49, has been our Vice President Finance since this past August. He previously acted as a consultant in various capacities in connection with MedTech fundraising and diligence. From 2019 to 2023, Mr. Gillings served as Vice President of Accelmed, a private equity investment firm focused on medical device companies. From 2018 to 2019 he served as Head of Investor Relations at Apollo Endosurgery, a MedTech company, and before that, from 2012 to 2018, he served as Vice President Equity Research with JMP Securities. Mr. Gillings holds a Masters in Finance from the London Business School, and a B.A. and M.A. in Accounting from the University of Utah. There are no changes to Mr. Gillings' compensation as a result of this designation, and there are no transactions or proposed transactions to which the Company is a party or intended to be a party in which Mr. Gillings has or will have a material interest subject to disclosure under Item 404(a) of Regulation S-K. Mr. Gillings does not have any family relationships with any current director, executive officer, or person nominated to become a director or executive officer, of the Company.

01

Item 7.01. Regulation FD Disclosure. On November 13, 2024, STRATA Skin Sciences, Inc. (the "Company") issued a press release announcing its results of operations for the first fiscal quarter ended June 30, 2024. The full text of such press release is furnished as Exhibit 99.1 to this report. The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. The following press release is furnished as an exhibit to this Current Report on Form 8-K pursuant to Item 2.02 and shall not be deemed to be "filed": 99.1 Press Release dated November 13, 2024 issued by STRATA Skin Sciences, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STRATA SKIN SCIENCES, INC. Date: November 13, 2024 By: /s/ John Gillings Chief Accounting Officer

View Full Filing

View this 8-K filing on SEC EDGAR